Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$1.17
-0.02-1.68%
At close: -
$1.18
0.010.85%
After Hours: 4:00 PM EDT
Comments
Loading...
AN2 Therapeutics Analyst Ratings and Price Targets | NASDAQ:ANTX | Benzinga
AN2 Therapeutics Inc has a consensus price target of $8.5 based on the ratings of 7 analysts. The high is $25 issued by SVB Leerink on November 14, 2022. The low is $2 issued by JMP Securities on May 5, 2025. The 3 most-recent analyst ratings were released by JMP Securities, Citizens Capital Markets, and Citizens Capital Markets on May 5, 2025, March 26, 2025, and February 25, 2025, respectively. With an average price target of $4 between JMP Securities, Citizens Capital Markets, and Citizens Capital Markets, there's an implied 238.98% upside for AN2 Therapeutics Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
JMP Securities
Citizens Capital Markets
Evercore ISI Group
SVB Leerink
1calculated from analyst ratings
Analyst Ratings for AN2 Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 05/05/2025 | Buy Now | 69.49% | JMP Securities | Roy Buchanan40% | $5 → $2 | Maintains | Market Outperform | Get Alert |
| 03/26/2025 | Buy Now | 323.73% | Citizens Capital Markets | Roy Buchanan40% | $5 → $5 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 02/25/2025 | Buy Now | 323.73% | Citizens Capital Markets | Roy Buchanan40% | $5 → $5 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 02/03/2025 | Buy Now | 323.73% | JMP Securities | Roy Buchanan40% | $5 → $5 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 11/19/2024 | Buy Now | 323.73% | JMP Securities | Roy Buchanan40% | $5 → $5 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 11/18/2024 | Buy Now | — | TD Cowen | Ritu Baral35% | — | Downgrade | Buy → Hold | Get Alert |
| 08/09/2024 | Buy Now | 154.24% | JMP Securities | Roy Buchanan40% | $6 → $3 | Maintains | Market Outperform | Get Alert |
| 07/03/2024 | Buy Now | — | Leerink Partners | Joseph Schwartz67% | — | Upgrade | Market Perform → Outperform | Get Alert |
| 05/16/2024 | Buy Now | 69.49% | Evercore ISI Group | Liisa Bayko71% | $7 → $2 | Maintains | In-Line | Get Alert |
| 04/02/2024 | Buy Now | 408.47% | JMP Securities | Roy Buchanan40% | → $6 | Upgrade | Market Perform → Market Outperform | Get Alert |
| 04/01/2024 | Buy Now | — | Oppenheimer | Jeff Jones34% | — | Reiterates | Perform → Perform | Get Alert |
| 02/13/2024 | Buy Now | 493.22% | Leerink Partners | Joseph Schwartz67% | $23 → $7 | Downgrade | Outperform → Market Perform | Get Alert |
| 02/12/2024 | Buy Now | 493.22% | Evercore ISI Group | Liisa Bayko71% | $25 → $7 | Downgrade | Outperform → In-Line | Get Alert |
| 02/12/2024 | Buy Now | — | Oppenheimer | Jeff Jones34% | — | Downgrade | Outperform → Perform | Get Alert |
| 02/12/2024 | Buy Now | — | JMP Securities | Roy Buchanan40% | — | Downgrade | Market Outperform → Market Perform | Get Alert |
| 01/04/2024 | Buy Now | 2442.37% | JMP Securities | Roy Buchanan40% | → $30 | Initiates | → Market Outperform | Get Alert |
| 03/30/2023 | Buy Now | 1933.9% | Oppenheimer | Jeff Jones34% | $20 → $24 | Maintains | Outperform | Get Alert |
| 11/14/2022 | Buy Now | 2018.64% | SVB Leerink | Joseph Schwartz67% | $27 → $25 | Maintains | Outperform | Get Alert |
FAQ
What is the target price for AN2 Therapeutics (ANTX) stock?
The latest price target for AN2 Therapeutics (NASDAQ:ANTX) was reported by JMP Securities on May 5, 2025. The analyst firm set a price target for $2.00 expecting ANTX to rise to within 12 months (a possible 69.49% upside). 8 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for AN2 Therapeutics (ANTX)?
The latest analyst rating for AN2 Therapeutics (NASDAQ:ANTX) was provided by JMP Securities, and AN2 Therapeutics maintained their market outperform rating.
When was the last upgrade for AN2 Therapeutics (ANTX)?
The last upgrade for AN2 Therapeutics Inc happened on July 3, 2024 when Leerink Partners raised their price target to N/A. Leerink Partners previously had a market perform for AN2 Therapeutics Inc.
When was the last downgrade for AN2 Therapeutics (ANTX)?
The last downgrade for AN2 Therapeutics Inc happened on November 18, 2024 when TD Cowen changed their price target from N/A to N/A for AN2 Therapeutics Inc.
When is the next analyst rating going to be posted or updated for AN2 Therapeutics (ANTX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of AN2 Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for AN2 Therapeutics was filed on May 5, 2025 so you should expect the next rating to be made available sometime around May 5, 2026.
Is the Analyst Rating AN2 Therapeutics (ANTX) correct?
While ratings are subjective and will change, the latest AN2 Therapeutics (ANTX) rating was a maintained with a price target of $5.00 to $2.00. The current price AN2 Therapeutics (ANTX) is trading at is $1.18, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
